Gastrointestinal Stromal Tumors Presenting as Surgical Emergencies: A Six-Patient Case Series

• Fazilet Erozgen

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

• Hüseyin Kadioglu

  Bezmialem Vakif University, Medical Faculty, Department of General Surgery, Istanbul, Turkey

• Mehmet Celal Kizilkaya

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

• Muzaffer Akinci

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

• Ahmet Kocakusak

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

• Adnan Hut

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

• Mehmet Gülen

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

• Ömer Güngörür

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

• Rafet Kaplan

  Department of General Surgery, Haseki Training and Research Hospital, Istanbul, Turkey

 Aim: To evaluate surgical and oncologic outcomes of patients who underwent urgent exploratory laparotomy, and successful surgical resection of gastrointestinal stromal tumors.

Methods: Medical records were retrospectively searched from January 2005 to January 2012 for cases with gastrointestinal stromal tumors, who had undergone urgent exploratory laparotomy.

Results: Of 51 patients operated for GISTs from January 2005 to January 2012, 6 cases had undergone urgent exploratory laparotomy and surgical resection. Our study group consisted of 4 female (66.6 %) and 2 male (33.4 %) patients with a median age of 60 years (range: 35-76 yrs). Their tumors were located in the stomach (n=1), jejunum (n=2), ileum (n=2), and rectum (n=1). For these tumors, total gastrectomy (n=1), segmental resection of the jejunum (n=2) or ileum (n=2), and left hemicolectomy (n=1) were performed followed by an uneventful postoperative course in all patients. According to Fletcher criteria, five tumors (83.3%) were classified as intermediate and high risk. No postoperative morbidity and mortality were noted. All patients received postoperative treatment with a tyrosine kinase inhibitor, imatinib. Median length of the hospital stay was 8 (range: 6 to 12) days. With a median follow-up of 32 (range 3 to 64) months, disease-free survival rate was 100 percent.

Conclusions: Although quite rare, patients with gastrointestinal stromal tumors may suffer from occult gastrointestinal hemorrhage and abdominal pain as the first clinical manifestations leading to urgent exploratory laparotomy and surgical extirpation of the tumor.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-78.

Scarpa M, Bertin M, Ruffolo C, Polese L, D’Amico DF, Angriman I. A systematic review on the clinical diagnosis of gastrotintestinal stromal tumor. J Surg Oncol 2008; 98: 384-92. http://dx.doi.org/10.1002/jso.21120

Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12. http://dx.doi.org/10.1007/s004280000338

Lev D, Kariv JI, Issakov J, Merhav H, Berger E, Merimsky J, et al. Gastrointestinal stromal sarcomas. Br J Surg 1999; 86: 545-9. http://dx.doi.org/10.1046/j.1365-2168.1999.01075.x

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65. http://dx.doi.org/10.1053/hupa.2002.123545

Emory TS, Sobin LH, Lukes L, Lee DH, O´Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7. http://dx.doi.org/10.1097/00000478-199901000-00009

Morgan BK, Compton C, Talbert M, Gallagher WJ, Wood WC. Benign smooth muscle tumors of the gastrointestinal tract. Ann Surg 1990; 211: 63. http://dx.doi.org/10.1097/00000658-199001000-00011

Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38: S39-51. http://dx.doi.org/10.1016/S0959-8049(02)80602-5

Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classifi cation based on tumor size and MIB-1 grade. Hum Pathol 2002; 33: 669-79. http://dx.doi.org/10.1053/hupa.2002.124116

Biasco G, Velo D, Angriman I, Astorino M, Baldan A, Baseggio M, et al.; Section of Oncology of the Italian Society of Gastroenterology; Interdisciplinary GIST Group-G.I.GIST, Veneto Institute of Oncology IOV-IRCCS Azienda Ospedale, University of Padua; GIST Study Group, Bologna University. Gastrointestinal stromal tumors: Report of an audit and review of the literature. Eur J Cancer Prev 2009; 18: 106-16. http://dx.doi.org/10.1097/CEJ.0b013e32830c8da8

Chen TW, Liu HD, Shyu RY, Yu JC, Shih ML, Chang TM, Hsieh CB. Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571. World J Gastroenterol 2005; 11: 260-63.

Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, Bonvalot S. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumors. Eur J Surg Oncol 2004; 30: 1098-103. http://dx.doi.org/10.1016/j.ejso.2004.06.016

Sakurai S, Hasegawa T, Sakuma Y, Takazawa Y, Motegi A, Nakajima T, et al. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infi ltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol 2004; 35: 1223-30. http://dx.doi.org/10.1016/j.humpath.2004.07.008

Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34. http://dx.doi.org/10.1016/S0140-6736(04)17098-0

• PDF